Native Antigen Company

Executive Summary

The Native Antigen Company is a UK-based leader in infectious disease reagents, providing cutting-edge antigens and antibodies for research, diagnostics, and vaccine development. Founded in 2012 and headquartered in Oxford, the company specializes in native and recombinant antigens for a wide range of pathogens, including emerging viruses and antimicrobial-resistant bacteria. Its products are critical for assay development, serological testing, and vaccine efficacy studies. The company serves a global customer base across academia, biotech, and pharmaceutical sectors. Despite operating in a competitive market, Native Antigen Company has carved a niche by emphasizing high-quality, biologically relevant reagents that closely mimic natural infection. The company's growth is supported by increasing demand for infectious disease diagnostics and vaccine R&D, particularly following the COVID-19 pandemic. However, as a private firm, financial details are limited, and its market share relative to larger reagent suppliers like Sino Biological or Thermo Fisher is modest. The company's ability to innovate and expand its product catalog will be key to capturing more opportunities in the expanding infectious disease diagnostics market.

Upcoming Catalysts (preview)

• Q3 2026Launch of new antigen panels for emerging viral threats70% success
• Q4 2026Strategic partnership with a major diagnostics firm50% success
• TBDExpansion of recombinant protein production capacity80% success